Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02726503
Other study ID # TRIHN1504
Secondary ID UMIN000020773
Status Completed
Phase Phase 2
First received
Last updated
Start date April 4, 2016
Est. completion date March 20, 2020

Study information

Verified date June 2020
Source Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this phase Ⅱ study is to assess the efficacy and safety of lenvatinib for anaplastic thyroid cancer patients who are diagnosed as unresectable. The total duration of the study will be 30 months. All patients will start administration of lenvatinib within 1 week of enrollment and receive the study drug 24mg orally once daily at almost the same time. 1 cycle consists of 4 weeks. Treatment term starts on the day 1st of drug administration of cycle 1 and administration will be continued until patients meet withdrawal criteria. Safety and efficacy assesment will be conducted on a regular basis during the trial. Tumor evaluation will be conducted at 4weeks, 8 weeks, 12 weeks, 16 weeks and at every 8 weeks after the 16th week since initial administration. When study drug administration terminated,tests of the drug termination will be conducted within 7 days of withdrawal and final observation will be conducted at 30 days after the last dose. Survival survey will be conducted at follow-up term. After the termination of the study drug, survival follow up survey will be conducted every 12 weeks unless patients withdraw enrollment of this study.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date March 20, 2020
Est. primary completion date February 25, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Histologically confirmed as anaplastic thyroid cancer

2. Unresectable disease

3. Have measurable lesion defined by the RECIST version 1.1

4. Have adequate organ function and meet following laboratory value:

1. Bone marrow function test within 14 days prior to enrollment:

neutrophil count>=1.5 x 103/microL blood platelet count>=10.0 x 104/microL hemoglobin amount>=9.0 g/dL

2. Liver function test within 14 days prior to enrollment:

AST,ALT<=3.0 x ULN(without liver metastatic) AST,ALT<=5.0 x ULN(with liver metastatic) bilirubin<=2.0 mg/dL

3. Kidney function test within 14 days prior to enrollment:

GFR estimation>=50 ml/min/1.73 m2 GFR estimation calculated by following formula. Male:194 x(serum creatinine concentration)-1.094 x(Age)-0.287 Female:Male GFR estimation x 0.739

4. Cardiac function test within 28 days prior to enrollment: 12-lead electrocardiogram: no clinically important abnormality as shown below: heart disease, severe arrhythmia etc.

5. Regardless of usage of antihypertensive drug, systolic blood pressure <=140 mm Hg and diastolic blood pressure <=90 mm Hg (If already taking antihypertensive drug, must have capacity of further antihypertensive therapy.)

6. ECOG performance status 0-2

7. Ability to swallow oral medications

8. Life expectancy greater than 8 weeks

9. Have signed written informed consent to participate in this study

Exclusion Criteria:

1. Have complications or medical history of

1. Complication of brain metastasis (Exclude if cured and in clinically stable condition for more than 1 month prior to screening.)

2. Treatment required complication of systemic infectious disease

3. Complication of pulmonary fibrosis or interstitial pneumonitis

4. Medical history of clinically significant cardiovascular disease within 6 months of initial dose as: NYHA class above 2 leveled congestive heart failure, unstable angina, cardiac infarction or cardiac arrhythmia with paroxysmal or required treatment e) Uncontrollable complication of diabetes mellitus f) hemoptysis within 3 weeks of enrollment (blood volume of more than half of teaspoon) g) Medical history of hemorrhagic or thrombotic disease within 6 months of enrollment h) If proteinuria values above 2+ by urinary protein qualitative test, conduct 24-hour urine collection and the urine protein determined as 1g/24 hours or more. (can substitute to the ratio of proteinuria in morning urine/creatinine) i) Malabsorption at gastrointestinal tract and any of the complication diseases that investigator considers that will be affected to lenvatinib absorption j) Recent major surgery within 2 weeks (if needle biopsy within 1 week) of enrollment k) Drainage required celomic fluid stagnation

2. Have history of lenvatinib administration

3. Confirmed tumor invasion to the carotid arteries

4. Have history of high dose external radiation therapy to cervical region, and irradiated tumor location close to the carotid arteries.

5. Have any unresolved toxicity greater than 1 by CTCAE v4.0.

6. Have active double cancer

7. Female patients who are pregnant, lactating, breast feeding or have childbearing potential

8. Psychiatric disorder and regarded by the investigator as inadequate for this study enrollment

9. Confirmed as no resistance to any component of this drug

10. Currently receiving other interventional clinical study treatment

Study Design


Intervention

Drug:
Lenvatinib
All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks. The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria.

Locations

Country Name City State
Japan Nippon Medical School Hospital Bunkyo-ku Tokyo-metropolis
Japan IUHW Ichikawa Hospital Ichikawa-city Chiba-prefecture
Japan Nara Hospital Kinki University Faculty of Medicine Ikoma-city Nara-prefecture
Japan Nara Medical University Kashihara-city Nara-prefecture
Japan National Cancer Center Hospital East Kashiwa-city Chiba-prefecture
Japan Kobe Univbersity Hospital Kobe-city Hyogo-prefecture
Japan Kuma Hospital Kobe-city Hyogo-prefecture
Japan The Cancer Institute Hospital of JFCR Koto-ku Tokyo-metropolis
Japan Shinsyu University School of Medicine Department of Surgery Matsumoto-city Nagano-prefecture
Japan Iwate Medical University Hospital Morioka-city Iwate-prefecture
Japan Nagoya University Hospital Nagoya-city Aichi-prefecture
Japan Japanese Red Cross Narita Hospital Narita-city Chiba-prefecture
Japan Miyaghi Cancer Center Natori-city Miyagi-prefecture
Japan Osaka City University Graduate School of Medicine and Faculty of Medicine Osaka-city Osaka-prefecture
Japan Osaka Police Hospital Osaka-city Osaka-prefecture
Japan Kitasato University Hospital Sagamihara-city Kanagawa-prefecture
Japan Tohoku University Hospital Sendai-city Miyagi-prefecture
Japan Ito Hospital Shibuya-ku Tokyo-metropolis
Japan Tokyo Medical University Hospital Shinjuku-ku Tokyo-metropolis
Japan Fujita Health University Hospital Toyoake-city Aichi-prefecture
Japan University of Tsukuba Hospital Tsukuba-city Ibaraki-prefecture
Japan Kanagawa Cancer Center Yokohama-city Kanagawa-prefecture
Japan Showa University Northern Yokohama Hospital Yokohama-city Kanagawa-prefecture

Sponsors (1)

Lead Sponsor Collaborator
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival (OS) OS is defined as time frame from date of initial dose until date of death from any cause. Or until the last confirmed survival date, study cut-off date which ever comes first. up to 30 months
Secondary Progression-Free Survival (PFS) PFS is defined as time frame from date of initial dose until the date of first confirmed disease progression, until date of death from any cause or the last tumor evaluating date whichever comes first. up to 30 months
Secondary Best Overall Response (BOR) BOR is defined as the best total efficacy record during the date of initial dose to the date of study completion, by which evaluated with following index. Complete Response (CR), Partial Response (PR), Stable Disease (SD is defined as ?3 weeks),Pharmacodynamics/Progressive Disease (PD) or Not Evaluable (NE). up to 30 months
Secondary Objective Response Rate (ORR) ORR is defined as the ratio of patients who are evaluated as CR or PR in Best Overall Response (BOR). up to 30 months
Secondary Disease Control Rate (DCR) DCR is defined as the ratio of patients who are evaluated as CR, PR or SD in Best Overall Response (BOR). up to 30 months
Secondary Clinical Benefit Rate (CBR) CBR is defined as the ratio of patients who are evaluated as CR, PR or durable SD (dSD is defined as ?11 weeks SD) in Best Overall Response (BOR). up to 30 months
Secondary Safety assessment on the incidence ratio of adverse events Safety assessment will be assessed by the ratio of adverse event up to 30 months
See also
  Status Clinical Trial Phase
Recruiting NCT04420754 - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer Phase 1
Completed NCT02152137 - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Active, not recruiting NCT04552769 - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Completed NCT02688608 - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Terminated NCT00095693 - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Phase 2
Active, not recruiting NCT01240590 - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Phase 1/Phase 2
Not yet recruiting NCT05819593 - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting NCT04579757 - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06374602 - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06362694 - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Phase 2
Withdrawn NCT01701349 - Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Phase 3
Active, not recruiting NCT03085056 - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Early Phase 1
Recruiting NCT01774279 - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Terminated NCT00126568 - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Completed NCT02244463 - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Phase 1/Phase 2
Active, not recruiting NCT05696548 - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) Phase 2
Terminated NCT00603941 - A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel Phase 1/Phase 2
Completed NCT00280852 - Review of Multimodality Management of Anaplastic Thyroid Cancer N/A
Recruiting NCT04238624 - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Phase 2